US 12,129,302 B2
Anti-CD-25 antibody
Dillon Phan, La Jolla, CA (US); Martin Brenner, Bryan, TX (US); Brian Berquist, Bryan, TX (US); Peter Kipp, Bryan, TX (US); Tam Phuong, San Diego, CA (US); Kevin Babilonia, Bryan, TX (US); Tom Hsu, Chino, CA (US); Lufei Hu, Escondido, CA (US); James Talmage Taylor, Jr., College Station, TX (US); and Cory Schwartz, San Diego, CA (US)
Assigned to iBio, Inc., Bryan, TX (US)
Filed by iBio, Inc., Bryan, TX (US)
Filed on Aug. 22, 2022, as Appl. No. 17/821,295.
Claims priority of provisional application 63/339,182, filed on May 6, 2022.
Claims priority of provisional application 63/312,213, filed on Feb. 21, 2022.
Claims priority of provisional application 63/237,100, filed on Aug. 25, 2021.
Prior Publication US 2023/0159646 A1, May 25, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/567 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
 
1. A humanized anti-CD25 or binding fragment thereof that binds human CD25, which comprises:
a variable heavy chain comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 1 or 9 and comprises complementarity determining regions (CDRs) identical to the CDRs in the amino acid sequence of SEQ ID NO: 1 or 9; and
a variable light chain comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 4 or 11 and comprises complementarity determining regions (CDRs) identical to the CDRs in the amino acid sequence of SEQ ID NO: 4 or 11.